Rock Springs Capital
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to
Business Model: B2B
Revenue: $9.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Rock Springs Capital Information
Geographic Data
Address: 650 S Exeter St
City: Baltimore
State: MD
Zip: 21202
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$823M
Social
Crunchbase
Metrics
5,414,657Website Global Rank
1,710Website Monthly Traffic
Twitter Followers
Description
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.
Contact Phone:
+14102200129
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 4/2015 | Mirna Therapeutics | Series D | 0 |
| 10/2021 | Patina | Series A | 50M |
| 12/2018 | Vedanta Biosciences | Series C | 0 |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 5/2020 | Pulmonx | Equity | 66M |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 12/2017 | Aptinyx | Series B | 70M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 10/2020 | Honor | Series D | 140M |
| 7/2021 | dMed | Series C | 0 |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 8/2020 | Freenome | Series C | 270M |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 2/2015 | Chiasma | Series E | 70M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 5/2021 | Caris Life Sciences | Private Equity Round | 0 |
| 4/2019 | Inozyme | Series A | 67.4M |
| 9/2015 | Corvus Pharmaceuticals | Series B | 75M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 12/2014 | Sagimet Biosciences | Series D | 28.5M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 10/2022 | Treeline Biosciences | Series A | 261.3M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 12/2021 | Freenome | Series D | 300M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 12/2017 | Allakos | Series B | 100M |
| 6/2015 | Clementia Pharmaceuticals | Venture Round | 0 |
| 2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2020 | Everest Medicines | Series C | 310M |
| 7/2015 | Translate Bio | Series B | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 6/2016 | Vedanta Biosciences | Private Equity Round | 0 |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 2/2022 | MiRXES | Series C | 0 |
| 6/2015 | Advanced Accelerator Applications | Venture Round | 25.7M |
| 6/2021 | Apollo Therapeutics | Venture Round | 139.4M |
| 8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2023 | Hemab | Series B | 0 |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 7/2020 | Kindbody | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 9/2015 | AveXis | Series D | 65M |
| 11/2020 | Acumen Pharmaceuticals | Series B | 0 |
| 5/2020 | Atea | Series D | 215M |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 11/2017 | resTORbio | Series A | 40M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2021 | Sagimet Biosciences | Venture Round | 0 |
| 10/2014 | Invitae | Series F | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 4/2015 | Merus | Series C | 79.1M |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 3/2015 | Mersana Therapeutics | Series B | 35M |
| 2/2021 | Personal Genome Diagnostics | Series C | 0 |
| 8/2014 | Dermira | Series C | 51M |
| 11/2014 | Nivalis Therapeutics | Venture Round | 30M |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 12/2020 | Genesis Therapeutics | Series A | 52M |
| 3/2020 | Immunocore | Series B | 0 |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2015 | Adaptive Biotechnologies | Series F | 195M |
| 6/2017 | Zai Lab | Series C | 30M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 11/2013 | TriVascular | Series E | 0 |
| 4/2014 | Adverum Biotechnologies | Series B | 55M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 6/2021 | Synthekine | Series B | 0 |
| 11/2015 | ObsEva | Series B | 58.9M |
| 7/2020 | New Horizon Health | Series E | 30M |
| 7/2021 | Clinipace | Venture Round | 0 |
| 5/2017 | Synlogic | Series C | 42M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 7/2021 | Vedanta Biosciences | Series D | 0 |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 6/2018 | Kaleido | Series C | 101M |
| 7/2021 | MiRXES | Series C | 0 |
| 7/2021 | Imperative Care | Series D | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 10/2021 | Honor | Series E | 70M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 5/2015 | BeiGene | Series B | 97M |
| 5/2014 | Spark Therapeutics | Series B | 72.8M |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2019 | Imperative Care | Series C | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2022 | MiRXES | Series C | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
